Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026)
Corvus Pharmaceuticals (CRVS) recorded quarterly Capital Expenditures of $91000.0 in Q1 2026, up 264.0% quarter-over-quarter from $25000.0 in Q4 2025, and up 152.78% on a YoY basis from $36000.0 in Q1 2025.
Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Capital Expenditures history runs 9 years deep, the most recent figure standing at $91000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 152.78% year-over-year to $91000.0; the TTM figure through Mar 2026 stood at $229000.0 (up 536.11% YoY), while the FY2025 annual figure was $174000.0, changed N/A from the prior year.
- Capital Expenditures was $91000.0 for Q1 2026 at Corvus Pharmaceuticals, up from $25000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $265000.0 in Q3 2022 to a low of $25000.0 in Q4 2025.
- Historically, Capital Expenditures has averaged $94000.0 across 4 years, with a median of $63500.0 in 2025.
- Biggest YoY gain for Capital Expenditures was 152.78% in 2026; the steepest drop was 152.78% in 2026.
- A 4-year view of Capital Expenditures shows it stood at $265000.0 in 2022, then tumbled by 87.17% to $34000.0 in 2023, then slipped by 26.47% to $25000.0 in 2025, then jumped by 264.0% to $91000.0 in 2026.
- The last three Capital Expenditures figures came in at $91000.0 (Q1 2026), $25000.0 (Q4 2025), and $113000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -63,220.27 |
| 10 | Corvus Pharmaceuticals | 1.00 Bn | 766.75 Mn | - | 91,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 91,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Jun 30, 2025 | 113,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2025 | 36,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Mar 31, 2023 | 34,000.00 |
| Sep 30, 2022 | 265,000.00 |
| Sep 30, 2022 | 265,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Dec 31, 2019 | 5,000.00 |
| Sep 30, 2019 | 4,000.00 |
| Sep 30, 2019 | 4,000.00 |
| Mar 31, 2019 | 16,000.00 |
| Mar 31, 2019 | 16,000.00 |
| Dec 31, 2018 | 78,000.00 |
| Dec 31, 2018 | 78,000.00 |